April 24, 2017 / 11:14 AM / 7 months ago

BRIEF-Cara Therapeutics announces positive data

April 24 (Reuters) - Cara Therapeutics Inc:

* Cara Therapeutics announces positive data from quantitative phase 1 trial measuring respiratory safety of I.V. CR845

* Cara Therapeutics-trial showing that I.V. CR845 did not significantly differ from placebo across 3 quantitative measures of respiratory drive in healthy individuals

* Cara Therapeutics - reported treatment-emergent adverse events were previously reported with CR845 administration; were mild, resolving without intervention Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below